quantigene singleplex assay kit 96-well plate format (Thermo Fisher)
Thermo Fisher is a verified supplier 
Thermo Fisher manufactures this product 
90
Structured Review
Thermo Fisher
quantigene singleplex assay kit 96-well plate format
Quantigene Singleplex Assay Kit 96 Well Plate Format, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quantigene+singleplex+assay+kit+96-well+plate+format/96+well+plates/pm37256266-85-9-26
Average 90 stars, based on 1 article reviews
Quantigene Singleplex Assay Kit 96 Well Plate Format, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quantigene+singleplex+assay+kit+96-well+plate+format/96+well+plates/pm37256266-85-9-26
Average 90 stars, based on 1 article reviews
quantigene singleplex assay kit 96-well plate format - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Expressing:Article Title: Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice. Article Snippet: RESEARCH ARTICLE | MAY 31 2023 Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice Benedikt Kaufmann; ... et. al J Immunol (2023) 211 (2): 287–294. https://doi.org/10.4049/jimmunol.2200550 Related Content Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides Immunohorizons (February,2021) Immunomodulation with IL-4Rα Antisense Oligonucleotide Prevents Respiratory Syncytial Virus-Mediated Pulmonary Disease J Immunol (October,2010) Modi cation of MyD88 mRNA Splicing and Inhibition of IL-1β Signaling in Cell Culture and in Mice with a 2′-O-MethoxyethylModi ed Oligonucleotide J Immunol (March,2006) D ow nloaded from http://journals.aai.org/jim m unol/article-pdf/211/2/287/1646792/ji2200550.pdf by U niversity of Bristol Library user on 27 January 2024 Antisense Oligonucleotide Therapy Decreases IL-1b Expression and Prolongs Survival in Mutant Nlrp3 Mice Benedikt Kaufmann,*,† Marta de Los Reyes Jiménez,‡ Laela M. Booshehri,* Janset Onyuru,* Aleksandra Leszczynska,* Anna Uri,‡ Sven Michel,‡ Richard Klar,‡ Frank Jaschinski,‡ Ariel E. Feldstein,*,§,1 Lori Broderick,*,§,1 and Hal M. Hoffman*,§,1 Antisense oligonucleotides (ASOs) are a novel therapeutic strategy that targets a specific gene and suppresses its expression.. The cryopyrinassociated periodic syndromes (CAPS) are a spectrum of autoinflammatory diseases characterized by systemic and tissue inflammation that is caused by heterozygous gain-of-function mutations in the nucleotide-binding and oligomerization domain-like receptor (NLR) family pyrin domain containing 3 (NLRP3) gene.. The aim of this study was to investigate the efficacy of an Nlrp3-specific ASO treatment in CAPS. Article Title: Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity Article Snippet: Article Title: A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression. Article Snippet: Tumors can utilize a diverse repertoire of immunosuppressive mechanisms to evade attack by the immune system.. Despite promising success with blockade of immune checkpoints like PD-1 the majority of patients does not respond to current immunotherapies.. The degradation of tryptophan into immunosuppressive kynurenine is an important immunosuppressive pathway. Singleplex Assay:Article Title: Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice. Article Snippet: RESEARCH ARTICLE | MAY 31 2023 Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice Benedikt Kaufmann; ... et. al J Immunol (2023) 211 (2): 287–294. https://doi.org/10.4049/jimmunol.2200550 Related Content Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides Immunohorizons (February,2021) Immunomodulation with IL-4Rα Antisense Oligonucleotide Prevents Respiratory Syncytial Virus-Mediated Pulmonary Disease J Immunol (October,2010) Modi cation of MyD88 mRNA Splicing and Inhibition of IL-1β Signaling in Cell Culture and in Mice with a 2′-O-MethoxyethylModi ed Oligonucleotide J Immunol (March,2006) D ow nloaded from http://journals.aai.org/jim m unol/article-pdf/211/2/287/1646792/ji2200550.pdf by U niversity of Bristol Library user on 27 January 2024 Antisense Oligonucleotide Therapy Decreases IL-1b Expression and Prolongs Survival in Mutant Nlrp3 Mice Benedikt Kaufmann,*,† Marta de Los Reyes Jiménez,‡ Laela M. Booshehri,* Janset Onyuru,* Aleksandra Leszczynska,* Anna Uri,‡ Sven Michel,‡ Richard Klar,‡ Frank Jaschinski,‡ Ariel E. Feldstein,*,§,1 Lori Broderick,*,§,1 and Hal M. Hoffman*,§,1 Antisense oligonucleotides (ASOs) are a novel therapeutic strategy that targets a specific gene and suppresses its expression.. The cryopyrinassociated periodic syndromes (CAPS) are a spectrum of autoinflammatory diseases characterized by systemic and tissue inflammation that is caused by heterozygous gain-of-function mutations in the nucleotide-binding and oligomerization domain-like receptor (NLR) family pyrin domain containing 3 (NLRP3) gene.. The aim of this study was to investigate the efficacy of an Nlrp3-specific ASO treatment in CAPS. Article Title: Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity Article Snippet: Article Title: A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression. Article Snippet: Tumors can utilize a diverse repertoire of immunosuppressive mechanisms to evade attack by the immune system.. Despite promising success with blockade of immune checkpoints like PD-1 the majority of patients does not respond to current immunotherapies.. The degradation of tryptophan into immunosuppressive kynurenine is an important immunosuppressive pathway. Cell Culture:Article Title: Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice. Article Snippet: RESEARCH ARTICLE | MAY 31 2023 Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice Benedikt Kaufmann; ... et. al J Immunol (2023) 211 (2): 287–294. https://doi.org/10.4049/jimmunol.2200550 Related Content Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides Immunohorizons (February,2021) Immunomodulation with IL-4Rα Antisense Oligonucleotide Prevents Respiratory Syncytial Virus-Mediated Pulmonary Disease J Immunol (October,2010) Modi cation of MyD88 mRNA Splicing and Inhibition of IL-1β Signaling in Cell Culture and in Mice with a 2′-O-MethoxyethylModi ed Oligonucleotide J Immunol (March,2006) D ow nloaded from http://journals.aai.org/jim m unol/article-pdf/211/2/287/1646792/ji2200550.pdf by U niversity of Bristol Library user on 27 January 2024 Antisense Oligonucleotide Therapy Decreases IL-1b Expression and Prolongs Survival in Mutant Nlrp3 Mice Benedikt Kaufmann,*,† Marta de Los Reyes Jiménez,‡ Laela M. Booshehri,* Janset Onyuru,* Aleksandra Leszczynska,* Anna Uri,‡ Sven Michel,‡ Richard Klar,‡ Frank Jaschinski,‡ Ariel E. Feldstein,*,§,1 Lori Broderick,*,§,1 and Hal M. Hoffman*,§,1 Antisense oligonucleotides (ASOs) are a novel therapeutic strategy that targets a specific gene and suppresses its expression.. The cryopyrinassociated periodic syndromes (CAPS) are a spectrum of autoinflammatory diseases characterized by systemic and tissue inflammation that is caused by heterozygous gain-of-function mutations in the nucleotide-binding and oligomerization domain-like receptor (NLR) family pyrin domain containing 3 (NLRP3) gene.. The aim of this study was to investigate the efficacy of an Nlrp3-specific ASO treatment in CAPS. Article Title: Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity Article Snippet: Article Title: A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression. Article Snippet: Tumors can utilize a diverse repertoire of immunosuppressive mechanisms to evade attack by the immune system.. Despite promising success with blockade of immune checkpoints like PD-1 the majority of patients does not respond to current immunotherapies.. The degradation of tryptophan into immunosuppressive kynurenine is an important immunosuppressive pathway. |